The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Excision repair cross-complementing group-1 (ERCC1) gene induction in peripheral blood mononuclear cells as a marker of outcome in patients with colorectal cancer treated with oxaliplatin.
 
Devika Rao
Stock and Other Ownership Interests - Baxter (I)
 
Atrayee Basu Mallick
Research Funding - BMS,advachen,TRACON,LILLY,AGICC (Inst)
Travel, Accommodations, Expenses - Lilly
 
Amartej Merla
Consulting or Advisory Role - Celgene
 
Jeeshan Jiffry
No Relationships to Disclose
 
Imran Chaudhary
No Relationships to Disclose
 
Titto A Augustine
No Relationships to Disclose
 
Lakshmi Rajdev
Patents, Royalties, Other Intellectual Property - Bristol Myers Squibb, Boston Biomedical (Inst)
 
Andreas Kaubisch
Other Relationship - Johnson & Johnson
 
Radhashree Maitra
No Relationships to Disclose
 
Sanjay Goel
Research Funding - Oncolytics (Inst)
Patents, Royalties, Other Intellectual Property - I have a patent with a co-inventor, John Mariadason, Ph.D, entitled "Method Of Determining The Sensitivity Of Cancer Cells To EGFR Inhibitors Including Cetuximab, Panitumumab And Erlotinib.", Patent No. 20090258364